Evaluation of the Effectiveness of N-Acetylcysteine in the Prevention of Colistin-Induced Nephrotoxicity: A Randomized Controlled Clinical Trial.

IF 0.8 Q4 PHARMACOLOGY & PHARMACY

Journal of Research in Pharmacy Practice Pub Date : 2022-05-25 eCollection Date: 2021-10-01 DOI:10.4103/jrpp.jrpp_90_21

Sedigheh Mosayebi, Rasool Soltani, Fatemeh Shafiee, Samane Assarzadeh, Atousa Hakamifard

{"title":"Evaluation of the Effectiveness of N-Acetylcysteine in the Prevention of Colistin-Induced Nephrotoxicity: A Randomized Controlled Clinical Trial.","authors":"Sedigheh Mosayebi, Rasool Soltani, Fatemeh Shafiee, Samane Assarzadeh, Atousa Hakamifard","doi":"10.4103/jrpp.jrpp_90_21","DOIUrl":null,"url":null,"abstract":"Objective: The present study aimed to evaluate the effectiveness of N-Acetylcysteine (NAC), as an antioxidant, in preventing nephrotoxicity in patients receiving colistin.Methods: In a randomized controlled clinical trial, eligible participants receiving colistin were divided into two groups including drug (n = 43) and control (n = 39). In the drug group, 1200 mg of NAC was administered daily for 10 days concurrently with colistin. Patients in the control group received only colistin. The serum creatinine level (SCr), blood urea nitrogen (BUN), and creatinine clearance (CrCl) at baseline and every other day, and the number of cases with acute kidney injury (AKI) during the study were recorded. Before starting treatment and on day 5, the level of urinary neutrophil gelatinase-associated lipocalin (NGAL) was determined. Finally, the values were compared between the groups.Findings: There was a significant increase in SCr and BUN and a significant reduction in CrCl in both groups, but there was not any significant difference between the two groups at any time. Changes in the urine NGAL levels were not significantly different between the two groups. Even though the number of cases with AKI in the drug group (8 cases, 18.6%) was less than the control group (11 cases, 28.2%), the difference was not statistically significant (P = 0.303).Conclusion: Simultaneous administration of NAC with a dose of 1200 mg daily does not have any effect in the prevention of colistin-induced nephrotoxicity.","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 4","pages":"159-165"},"PeriodicalIF":0.8000,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/33/df/JRPP-10-159.PMC9235367.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Research in Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jrpp.jrpp_90_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 2

Abstract

Objective: The present study aimed to evaluate the effectiveness of N-Acetylcysteine (NAC), as an antioxidant, in preventing nephrotoxicity in patients receiving colistin.

Methods: In a randomized controlled clinical trial, eligible participants receiving colistin were divided into two groups including drug (n = 43) and control (n = 39). In the drug group, 1200 mg of NAC was administered daily for 10 days concurrently with colistin. Patients in the control group received only colistin. The serum creatinine level (SCr), blood urea nitrogen (BUN), and creatinine clearance (CrCl) at baseline and every other day, and the number of cases with acute kidney injury (AKI) during the study were recorded. Before starting treatment and on day 5, the level of urinary neutrophil gelatinase-associated lipocalin (NGAL) was determined. Finally, the values were compared between the groups.

Findings: There was a significant increase in SCr and BUN and a significant reduction in CrCl in both groups, but there was not any significant difference between the two groups at any time. Changes in the urine NGAL levels were not significantly different between the two groups. Even though the number of cases with AKI in the drug group (8 cases, 18.6%) was less than the control group (11 cases, 28.2%), the difference was not statistically significant (P = 0.303).

Conclusion: Simultaneous administration of NAC with a dose of 1200 mg daily does not have any effect in the prevention of colistin-induced nephrotoxicity.

Abstract Image

查看原文本刊更多论文

评价n-乙酰半胱氨酸预防粘菌素所致肾毒性的有效性:一项随机对照临床试验。

目的:本研究旨在评价n -乙酰半胱氨酸(NAC)作为抗氧化剂预防多粘菌素患者肾毒性的有效性。方法:采用随机对照临床试验，将符合条件的接受粘菌素治疗的受试者分为药物组(n = 43)和对照组(n = 39)。药物组每日给予NAC 1200mg，连续10天，同时给予粘菌素。对照组患者仅给予粘菌素治疗。记录两组患者基线及隔日血清肌酐水平(SCr)、血尿素氮(BUN)、肌酐清除率(CrCl)及研究期间急性肾损伤(AKI)病例数。在开始治疗前和第5天，测定尿中性粒细胞明胶酶相关脂钙蛋白(NGAL)水平。最后比较两组间的数值。结果:两组患者SCr、BUN均显著升高，CrCl均显著降低，但两组间任何时间均无显著差异。两组间尿NGAL水平变化无显著差异。药物组AKI发生率(8例，18.6%)虽低于对照组(11例，28.2%)，但差异无统计学意义(P = 0.303)。结论:每日1200mg同时给药NAC对预防粘菌素所致肾毒性无明显作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Research in Pharmacy Practice PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

审稿时长

21 weeks

期刊介绍： The main focus of the journal will be on evidence-based drug-related medical researches (with clinical pharmacists’ intervention or documentation), particularly in the Eastern Mediterranean region. However, a wide range of closely related issues will be also covered. These will include clinical studies in the field of pharmaceutical care, reporting adverse drug reactions and human medical toxicology, pharmaco-epidemiology and toxico-epidemiology (poisoning epidemiology), social aspects of pharmacy practice, pharmacy education and economic evaluations of treatment protocols (e.g. cost-effectiveness studies). Local reports of medication utilization studies at hospital or pharmacy levels will only be considered for peer-review process only if they have a new and useful message for the international pharmacy practice professionals and readers.